1
|
Cottingham E, Johnstone T, Vaz PK, Hartley CA, Devlin JM. Construction and in vitro characterisation of virus-vectored immunocontraceptive candidates derived from felid alphaherpesvirus 1. Vaccine 2024:S0264-410X(24)00615-7. [PMID: 38824082 DOI: 10.1016/j.vaccine.2024.05.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 05/16/2024] [Accepted: 05/20/2024] [Indexed: 06/03/2024]
Abstract
There is a pressing need for effective feral cat management globally due to overabundant feline populations, disease transmission and their destructive impact on biodiversity. Virus-vectored immunocontraception (VVIC) is an attractive method for cat population management. Virus-vectored immunocontraceptives could be self-disseminating through horizontal transmission of the VVIC in feral cat populations, or they may be modified to act as non-transmissible vaccine-type immunocontraceptives for delivery to individual cats. These later constructs may be particularly attractive for use in owned (pet) cats and stray cats but could also be used for feral cats that are caught, vaccinated, and released. Here, we report the construction of three felid alphaherpesvirus 1 (FHV-1) derived immunocontraceptive candidates containing genes that encode for feline zona pellucida subunit 3 (ZP3) and gonadotropin-releasing hormone (GnRH). Two of the vaccine candidates were engineered to include disruptions to the thymidine kinase viral virulence gene to reduce the ability of the vaccines to be horizontally transmitted. Analysis of in vitro growth characteristics and protein expression are reported, and their potential for use as a population management tool for cats is discussed.
Collapse
Affiliation(s)
- Ellen Cottingham
- The Asia Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria 3010, Australia.
| | - Thurid Johnstone
- ARH Essendon Fields, 72 Hargraves Ave, Melbourne (Essendon Fields), VIC 3014, Australia
| | - Paola K Vaz
- The Asia Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria 3010, Australia
| | - Carol A Hartley
- The Asia Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria 3010, Australia
| | - Joanne M Devlin
- The Asia Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria 3010, Australia
| |
Collapse
|
2
|
Goodrum F, Lowen AC, Lakdawala S, Alwine J, Casadevall A, Imperiale MJ, Atwood W, Avgousti D, Baines J, Banfield B, Banks L, Bhaduri-McIntosh S, Bhattacharya D, Blanco-Melo D, Bloom D, Boon A, Boulant S, Brandt C, Broadbent A, Brooke C, Cameron C, Campos S, Caposio P, Chan G, Cliffe A, Coffin J, Collins K, Damania B, Daugherty M, Debbink K, DeCaprio J, Dermody T, Dikeakos J, DiMaio D, Dinglasan R, Duprex WP, Dutch R, Elde N, Emerman M, Enquist L, Fane B, Fernandez-Sesma A, Flenniken M, Frappier L, Frieman M, Frueh K, Gack M, Gaglia M, Gallagher T, Galloway D, García-Sastre A, Geballe A, Glaunsinger B, Goff S, Greninger A, Hancock M, Harris E, Heaton N, Heise M, Heldwein E, Hogue B, Horner S, Hutchinson E, Hyser J, Jackson W, Kalejta R, Kamil J, Karst S, Kirchhoff F, Knipe D, Kowalik T, Lagunoff M, Laimins L, Langlois R, Lauring A, Lee B, Leib D, Liu SL, Longnecker R, Lopez C, Luftig M, Lund J, Manicassamy B, McFadden G, McIntosh M, Mehle A, Miller WA, Mohr I, Moody C, Moorman N, Moscona A, Mounce B, Munger J, Münger K, Murphy E, Naghavi M, Nelson J, Neufeldt C, Nikolich J, O'Connor C, Ono A, Orenstein W, Ornelles D, Ou JH, Parker J, Parrish C, Pekosz A, Pellett P, Pfeiffer J, Plemper R, Polyak S, Purdy J, Pyeon D, Quinones-Mateu M, Renne R, Rice C, Schoggins J, Roller R, Russell C, Sandri-Goldin R, Sapp M, Schang L, Schmid S, Schultz-Cherry S, Semler B, Shenk T, Silvestri G, Simon V, Smith G, Smith J, Spindler K, Stanifer M, Subbarao K, Sundquist W, Suthar M, Sutton T, Tai A, Tarakanova V, tenOever B, Tibbetts S, Tompkins S, Toth Z, van Doorslaer K, Vignuzzi M, Wallace N, Walsh D, Weekes M, Weinberg J, Weitzman M, Weller S, Whelan S, White E, Williams B, Wobus C, Wong S, Yurochko A. Virology under the Microscope-a Call for Rational Discourse. mSphere 2023; 8:e0003423. [PMID: 36700653 PMCID: PMC10117089 DOI: 10.1128/msphere.00034-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Viruses have brought humanity many challenges: respiratory infection, cancer, neurological impairment and immunosuppression to name a few. Virology research over the last 60+ years has responded to reduce this disease burden with vaccines and antivirals. Despite this long history, the COVID-19 pandemic has brought unprecedented attention to the field of virology. Some of this attention is focused on concern about the safe conduct of research with human pathogens. A small but vocal group of individuals has seized upon these concerns - conflating legitimate questions about safely conducting virus-related research with uncertainties over the origins of SARS-CoV-2. The result has fueled public confusion and, in many instances, ill-informed condemnation of virology. With this article, we seek to promote a return to rational discourse. We explain the use of gain-of-function approaches in science, discuss the possible origins of SARS-CoV-2 and outline current regulatory structures that provide oversight for virological research in the United States. By offering our expertise, we - a broad group of working virologists - seek to aid policy makers in navigating these controversial issues. Balanced, evidence-based discourse is essential to addressing public concern while maintaining and expanding much-needed research in virology.
Collapse
Affiliation(s)
- Felicia Goodrum
- Department of Immunobiology, BIO5 Institute, University of Arizona, Tucson, Arizona, USA
| | - Anice C Lowen
- Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Seema Lakdawala
- Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - James Alwine
- Department of Immunobiology, BIO5 Institute, University of Arizona, Tucson, Arizona, USA
- Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Arturo Casadevall
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Michael J Imperiale
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
| | | | - Daphne Avgousti
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | - Lawrence Banks
- International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | | | | | | | - David Bloom
- University of Florida, Gainesville, Florida, USA
| | - Adrianus Boon
- University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | | | - Curtis Brandt
- University of Wisconsin-Madison, Madison, Wisconsin, USA
| | | | | | - Craig Cameron
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | - Gary Chan
- SUNY Upstate Medical University, Syracuse, New York, USA
| | - Anna Cliffe
- University of Virginia, Charlottesville, Virginia, USA
| | - John Coffin
- Tufts University, Boston, Massachusetts, USA
| | | | - Blossom Damania
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | - Kari Debbink
- Johns Hopkins University, Baltimore, Maryland, USA
| | | | | | | | | | | | - W Paul Duprex
- University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | | | - Nels Elde
- University of Utah, Salt Lake City, Utah, USA
| | - Michael Emerman
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Lynn Enquist
- Princeton University, Princeton, New Jersey, USA
| | | | | | | | | | | | - Klaus Frueh
- Oregon Health and Science University, Beaverton, Oregon, USA
| | - Michaela Gack
- Florida Research and Innovation Center, Port Saint Lucie, Florida, USA
| | - Marta Gaglia
- University of Wisconsin-Madison, Madison, Wisconsin, USA
| | | | - Denise Galloway
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | - Adam Geballe
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | | | - Meaghan Hancock
- Oregon Health and Science University, Beaverton, Oregon, USA
| | - Eva Harris
- University of California, Berkeley, Berkeley, California, USA
| | | | - Mark Heise
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | | | | | | | | | | | - Jeremy Kamil
- Louisiana State University, Shreveport, Louisiana, USA
| | | | | | - David Knipe
- Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | - Ryan Langlois
- University of Minnesota, Minneapolis, Minnesota, USA
| | - Adam Lauring
- University of Michigan, Ann Arbor, Michigan, USA
| | - Benhur Lee
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - David Leib
- Dartmouth College, Lebanon, New Hampshire, USA
| | - Shan-Lu Liu
- The Ohio State University, Columbus, Ohio, USA
| | | | | | | | - Jennifer Lund
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | | | - Andrew Mehle
- University of Wisconsin-Madison, Madison, Wisconsin, USA
| | | | - Ian Mohr
- New York University, New York, New York, USA
| | - Cary Moody
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | | | | | - Karl Münger
- Tufts University, Boston, Massachusetts, USA
| | - Eain Murphy
- SUNY Upstate Medical University, Syracuse, New York, USA
| | | | - Jay Nelson
- Oregon Health and Science University, Beaverton, Oregon, USA
| | | | | | | | - Akira Ono
- University of Michigan, Ann Arbor, Michigan, USA
| | | | - David Ornelles
- Wake Forest University, Winston-Salem, North Carolina, USA
| | - Jing-Hsiung Ou
- University of Southern California, Los Angeles, California, USA
| | | | | | | | | | | | | | | | - John Purdy
- University of Arizona, Tucson, Arizona, USA
| | - Dohun Pyeon
- Michigan State University, East Lansing, Michigan, USA
| | | | - Rolf Renne
- University of Florida, Gainesville, Florida, USA
| | - Charles Rice
- The Rockefeller University, New York, New York, USA
| | | | | | - Charles Russell
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | | | - Martin Sapp
- Louisiana State University, Shreveport, Louisiana, USA
| | | | | | | | - Bert Semler
- University of California, Irvine, Irvine, California, USA
| | - Thomas Shenk
- Princeton University, Princeton, New Jersey, USA
| | | | - Viviana Simon
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | - Jason Smith
- University of Washington, Seattle, Washington, USA
| | | | | | - Kanta Subbarao
- The Peter Doherty Institute, Melbourne, Victoria, Australia
| | | | | | - Troy Sutton
- The Pennsylvania State University, University Park, Pennsylvania, USA
| | - Andrew Tai
- University of Michigan, Ann Arbor, Michigan, USA
| | | | | | | | | | - Zsolt Toth
- University of Florida, Gainesville, Florida, USA
| | | | | | | | - Derek Walsh
- Northwestern University, Chicago, Illinois, USA
| | | | | | | | - Sandra Weller
- University of Connecticut, Farmington, Connecticut, USA
| | - Sean Whelan
- Washington University, St. Louis, Missouri, USA
| | | | | | | | - Scott Wong
- Oregon Health and Science University, Beaverton, Oregon, USA
| | | |
Collapse
|
3
|
Goodrum F, Lowen AC, Lakdawala S, Alwine J, Casadevall A, Imperiale MJ, Atwood W, Avgousti D, Baines J, Banfield B, Banks L, Bhaduri-McIntosh S, Bhattacharya D, Blanco-Melo D, Bloom D, Boon A, Boulant S, Brandt C, Broadbent A, Brooke C, Cameron C, Campos S, Caposio P, Chan G, Cliffe A, Coffin J, Collins K, Damania B, Daugherty M, Debbink K, DeCaprio J, Dermody T, Dikeakos J, DiMaio D, Dinglasan R, Duprex WP, Dutch R, Elde N, Emerman M, Enquist L, Fane B, Fernandez-Sesma A, Flenniken M, Frappier L, Frieman M, Frueh K, Gack M, Gaglia M, Gallagher T, Galloway D, García-Sastre A, Geballe A, Glaunsinger B, Goff S, Greninger A, Hancock M, Harris E, Heaton N, Heise M, Heldwein E, Hogue B, Horner S, Hutchinson E, Hyser J, Jackson W, Kalejta R, Kamil J, Karst S, Kirchhoff F, Knipe D, Kowalik T, Lagunoff M, Laimins L, Langlois R, Lauring A, Lee B, Leib D, Liu SL, Longnecker R, Lopez C, Luftig M, Lund J, Manicassamy B, McFadden G, McIntosh M, Mehle A, Miller WA, Mohr I, Moody C, Moorman N, Moscona A, Mounce B, Munger J, Münger K, Murphy E, Naghavi M, Nelson J, Neufeldt C, Nikolich J, O'Connor C, Ono A, Orenstein W, Ornelles D, Ou JH, Parker J, Parrish C, Pekosz A, Pellett P, Pfeiffer J, Plemper R, Polyak S, Purdy J, Pyeon D, Quinones-Mateu M, Renne R, Rice C, Schoggins J, Roller R, Russell C, Sandri-Goldin R, Sapp M, Schang L, Schmid S, Schultz-Cherry S, Semler B, Shenk T, Silvestri G, Simon V, Smith G, Smith J, Spindler K, Stanifer M, Subbarao K, Sundquist W, Suthar M, Sutton T, Tai A, Tarakanova V, tenOever B, Tibbetts S, Tompkins S, Toth Z, van Doorslaer K, Vignuzzi M, Wallace N, Walsh D, Weekes M, Weinberg J, Weitzman M, Weller S, Whelan S, White E, Williams B, Wobus C, Wong S, Yurochko A. Virology under the Microscope-a Call for Rational Discourse. mBio 2023; 14:e0018823. [PMID: 36700642 PMCID: PMC9973315 DOI: 10.1128/mbio.00188-23] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Viruses have brought humanity many challenges: respiratory infection, cancer, neurological impairment and immunosuppression to name a few. Virology research over the last 60+ years has responded to reduce this disease burden with vaccines and antivirals. Despite this long history, the COVID-19 pandemic has brought unprecedented attention to the field of virology. Some of this attention is focused on concern about the safe conduct of research with human pathogens. A small but vocal group of individuals has seized upon these concerns - conflating legitimate questions about safely conducting virus-related research with uncertainties over the origins of SARS-CoV-2. The result has fueled public confusion and, in many instances, ill-informed condemnation of virology. With this article, we seek to promote a return to rational discourse. We explain the use of gain-of-function approaches in science, discuss the possible origins of SARS-CoV-2 and outline current regulatory structures that provide oversight for virological research in the United States. By offering our expertise, we - a broad group of working virologists - seek to aid policy makers in navigating these controversial issues. Balanced, evidence-based discourse is essential to addressing public concern while maintaining and expanding much-needed research in virology.
Collapse
Affiliation(s)
- Felicia Goodrum
- Department of Immunobiology, BIO5 Institute, University of Arizona, Tucson, Arizona, USA
| | - Anice C. Lowen
- Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Seema Lakdawala
- Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - James Alwine
- Department of Immunobiology, BIO5 Institute, University of Arizona, Tucson, Arizona, USA
- Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Arturo Casadevall
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Michael J. Imperiale
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
| | | | - Daphne Avgousti
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | - Lawrence Banks
- International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | | | | | | | - David Bloom
- University of Florida, Gainesville, Florida, USA
| | - Adrianus Boon
- University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | | | - Curtis Brandt
- University of Wisconsin—Madison, Madison, Wisconsin, USA
| | | | | | - Craig Cameron
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | - Gary Chan
- SUNY Upstate Medical University, Syracuse, New York, USA
| | - Anna Cliffe
- University of Virginia, Charlottesville, Virginia, USA
| | - John Coffin
- Tufts University, Boston, Massachusetts, USA
| | | | - Blossom Damania
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | - Kari Debbink
- Johns Hopkins University, Baltimore, Maryland, USA
| | | | | | | | | | | | | | | | - Nels Elde
- University of Utah, Salt Lake City, Utah, USA
| | - Michael Emerman
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Lynn Enquist
- Princeton University, Princeton, New Jersey, USA
| | | | | | | | | | | | - Klaus Frueh
- Oregon Health and Science University, Beaverton, Oregon, USA
| | - Michaela Gack
- Florida Research and Innovation Center, Port Saint Lucie, Florida, USA
| | - Marta Gaglia
- University of Wisconsin—Madison, Madison, Wisconsin, USA
| | | | - Denise Galloway
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | - Adam Geballe
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | | | - Meaghan Hancock
- Oregon Health and Science University, Beaverton, Oregon, USA
| | - Eva Harris
- University of California, Berkeley, Berkeley, California, USA
| | | | - Mark Heise
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | | | | | | | | | | | - Jeremy Kamil
- Louisiana State University, Shreveport, Louisiana, USA
| | | | | | - David Knipe
- Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | - Ryan Langlois
- University of Minnesota, Minneapolis, Minnesota, USA
| | - Adam Lauring
- University of Michigan, Ann Arbor, Michigan, USA
| | - Benhur Lee
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - David Leib
- Dartmouth College, Lebanon, New Hampshire, USA
| | - Shan-Lu Liu
- The Ohio State University, Columbus, Ohio, USA
| | | | | | | | - Jennifer Lund
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | | | - Andrew Mehle
- University of Wisconsin—Madison, Madison, Wisconsin, USA
| | | | - Ian Mohr
- New York University, New York, New York, USA
| | - Cary Moody
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | | | | | - Karl Münger
- Tufts University, Boston, Massachusetts, USA
| | - Eain Murphy
- SUNY Upstate Medical University, Syracuse, New York, USA
| | | | - Jay Nelson
- Oregon Health and Science University, Beaverton, Oregon, USA
| | | | | | | | - Akira Ono
- University of Michigan, Ann Arbor, Michigan, USA
| | | | - David Ornelles
- Wake Forest University, Winston-Salem, North Carolina, USA
| | - Jing-hsiung Ou
- University of Southern California, Los Angeles, California, USA
| | | | | | | | | | | | | | | | - John Purdy
- University of Arizona, Tucson, Arizona, USA
| | - Dohun Pyeon
- Michigan State University, East Lansing, Michigan, USA
| | | | - Rolf Renne
- University of Florida, Gainesville, Florida, USA
| | - Charles Rice
- The Rockefeller University, New York, New York, USA
| | | | | | - Charles Russell
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | | | - Martin Sapp
- Louisiana State University, Shreveport, Louisiana, USA
| | | | | | | | - Bert Semler
- University of California, Irvine, Irvine, California, USA
| | - Thomas Shenk
- Princeton University, Princeton, New Jersey, USA
| | | | - Viviana Simon
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | - Jason Smith
- University of Washington, Seattle, Washington, USA
| | | | | | - Kanta Subbarao
- The Peter Doherty Institute, Melbourne, Victoria, Australia
| | | | | | - Troy Sutton
- The Pennsylvania State University, University Park, Pennsylvania, USA
| | - Andrew Tai
- University of Michigan, Ann Arbor, Michigan, USA
| | | | | | | | | | - Zsolt Toth
- University of Florida, Gainesville, Florida, USA
| | | | | | | | - Derek Walsh
- Northwestern University, Chicago, Illinois, USA
| | | | | | | | - Sandra Weller
- University of Connecticut, Farmington, Connecticut, USA
| | - Sean Whelan
- Washington University, St. Louis, Missouri, USA
| | | | | | | | - Scott Wong
- Oregon Health and Science University, Beaverton, Oregon, USA
| | | |
Collapse
|
4
|
Goodrum F, Lowen AC, Lakdawala S, Alwine J, Casadevall A, Imperiale MJ, Atwood W, Avgousti D, Baines J, Banfield B, Banks L, Bhaduri-McIntosh S, Bhattacharya D, Blanco-Melo D, Bloom D, Boon A, Boulant S, Brandt C, Broadbent A, Brooke C, Cameron C, Campos S, Caposio P, Chan G, Cliffe A, Coffin J, Collins K, Damania B, Daugherty M, Debbink K, DeCaprio J, Dermody T, Dikeakos J, DiMaio D, Dinglasan R, Duprex WP, Dutch R, Elde N, Emerman M, Enquist L, Fane B, Fernandez-Sesma A, Flenniken M, Frappier L, Frieman M, Frueh K, Gack M, Gaglia M, Gallagher T, Galloway D, García-Sastre A, Geballe A, Glaunsinger B, Goff S, Greninger A, Hancock M, Harris E, Heaton N, Heise M, Heldwein E, Hogue B, Horner S, Hutchinson E, Hyser J, Jackson W, Kalejta R, Kamil J, Karst S, Kirchhoff F, Knipe D, Kowalik T, Lagunoff M, Laimins L, Langlois R, Lauring A, Lee B, Leib D, Liu SL, Longnecker R, Lopez C, Luftig M, Lund J, Manicassamy B, McFadden G, McIntosh M, Mehle A, Miller WA, Mohr I, Moody C, Moorman N, Moscona A, Mounce B, Munger J, Münger K, Murphy E, Naghavi M, Nelson J, Neufeldt C, Nikolich J, O'Connor C, Ono A, Orenstein W, Ornelles D, Ou JH, Parker J, Parrish C, Pekosz A, Pellett P, Pfeiffer J, Plemper R, Polyak S, Purdy J, Pyeon D, Quinones-Mateu M, Renne R, Rice C, Schoggins J, Roller R, Russell C, Sandri-Goldin R, Sapp M, Schang L, Schmid S, Schultz-Cherry S, Semler B, Shenk T, Silvestri G, Simon V, Smith G, Smith J, Spindler K, Stanifer M, Subbarao K, Sundquist W, Suthar M, Sutton T, Tai A, Tarakanova V, tenOever B, Tibbetts S, Tompkins S, Toth Z, van Doorslaer K, Vignuzzi M, Wallace N, Walsh D, Weekes M, Weinberg J, Weitzman M, Weller S, Whelan S, White E, Williams B, Wobus C, Wong S, Yurochko A. Virology under the Microscope-a Call for Rational Discourse. J Virol 2023; 97:e0008923. [PMID: 36700640 PMCID: PMC9972907 DOI: 10.1128/jvi.00089-23] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Viruses have brought humanity many challenges: respiratory infection, cancer, neurological impairment and immunosuppression to name a few. Virology research over the last 60+ years has responded to reduce this disease burden with vaccines and antivirals. Despite this long history, the COVID-19 pandemic has brought unprecedented attention to the field of virology. Some of this attention is focused on concern about the safe conduct of research with human pathogens. A small but vocal group of individuals has seized upon these concerns - conflating legitimate questions about safely conducting virus-related research with uncertainties over the origins of SARS-CoV-2. The result has fueled public confusion and, in many instances, ill-informed condemnation of virology. With this article, we seek to promote a return to rational discourse. We explain the use of gain-of-function approaches in science, discuss the possible origins of SARS-CoV-2 and outline current regulatory structures that provide oversight for virological research in the United States. By offering our expertise, we - a broad group of working virologists - seek to aid policy makers in navigating these controversial issues. Balanced, evidence-based discourse is essential to addressing public concern while maintaining and expanding much-needed research in virology.
Collapse
Affiliation(s)
- Felicia Goodrum
- Department of Immunobiology, BIO5 Institute, University of Arizona, Tucson, Arizona, USA
| | - Anice C. Lowen
- Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Seema Lakdawala
- Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - James Alwine
- Department of Immunobiology, BIO5 Institute, University of Arizona, Tucson, Arizona, USA
- Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Arturo Casadevall
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Michael J. Imperiale
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
| | | | - Daphne Avgousti
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | - Lawrence Banks
- International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | | | | | | | - David Bloom
- University of Florida, Gainesville, Florida, USA
| | - Adrianus Boon
- University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | | | - Curtis Brandt
- University of Wisconsin—Madison, Madison, Wisconsin, USA
| | | | | | - Craig Cameron
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | - Gary Chan
- SUNY Upstate Medical University, Syracuse, New York, USA
| | - Anna Cliffe
- University of Virginia, Charlottesville, Virginia, USA
| | - John Coffin
- Tufts University, Boston, Massachusetts, USA
| | | | - Blossom Damania
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | - Kari Debbink
- Johns Hopkins University, Baltimore, Maryland, USA
| | | | | | | | | | | | | | | | - Nels Elde
- University of Utah, Salt Lake City, Utah, USA
| | - Michael Emerman
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Lynn Enquist
- Princeton University, Princeton, New Jersey, USA
| | | | | | | | | | | | - Klaus Frueh
- Oregon Health and Science University, Beaverton, Oregon, USA
| | - Michaela Gack
- Florida Research and Innovation Center, Port Saint Lucie, Florida, USA
| | - Marta Gaglia
- University of Wisconsin—Madison, Madison, Wisconsin, USA
| | | | - Denise Galloway
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | - Adam Geballe
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | | | - Meaghan Hancock
- Oregon Health and Science University, Beaverton, Oregon, USA
| | - Eva Harris
- University of California, Berkeley, Berkeley, California, USA
| | | | - Mark Heise
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | | | | | | | | | | | - Jeremy Kamil
- Louisiana State University, Shreveport, Louisiana, USA
| | | | | | - David Knipe
- Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | - Ryan Langlois
- University of Minnesota, Minneapolis, Minnesota, USA
| | - Adam Lauring
- University of Michigan, Ann Arbor, Michigan, USA
| | - Benhur Lee
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - David Leib
- Dartmouth College, Lebanon, New Hampshire, USA
| | - Shan-Lu Liu
- The Ohio State University, Columbus, Ohio, USA
| | | | | | | | - Jennifer Lund
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | | | - Andrew Mehle
- University of Wisconsin—Madison, Madison, Wisconsin, USA
| | | | - Ian Mohr
- New York University, New York, New York, USA
| | - Cary Moody
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | | | | | - Karl Münger
- Tufts University, Boston, Massachusetts, USA
| | - Eain Murphy
- SUNY Upstate Medical University, Syracuse, New York, USA
| | | | - Jay Nelson
- Oregon Health and Science University, Beaverton, Oregon, USA
| | | | | | | | - Akira Ono
- University of Michigan, Ann Arbor, Michigan, USA
| | | | - David Ornelles
- Wake Forest University, Winston-Salem, North Carolina, USA
| | - Jing-hsiung Ou
- University of Southern California, Los Angeles, California, USA
| | | | | | | | | | | | | | | | - John Purdy
- University of Arizona, Tucson, Arizona, USA
| | - Dohun Pyeon
- Michigan State University, East Lansing, Michigan, USA
| | | | - Rolf Renne
- University of Florida, Gainesville, Florida, USA
| | - Charles Rice
- The Rockefeller University, New York, New York, USA
| | | | | | - Charles Russell
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | | | - Martin Sapp
- Louisiana State University, Shreveport, Louisiana, USA
| | | | | | | | - Bert Semler
- University of California, Irvine, Irvine, California, USA
| | - Thomas Shenk
- Princeton University, Princeton, New Jersey, USA
| | | | - Viviana Simon
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | - Jason Smith
- University of Washington, Seattle, Washington, USA
| | | | | | - Kanta Subbarao
- The Peter Doherty Institute, Melbourne, Victoria, Australia
| | | | | | - Troy Sutton
- The Pennsylvania State University, University Park, Pennsylvania, USA
| | - Andrew Tai
- University of Michigan, Ann Arbor, Michigan, USA
| | | | | | | | | | - Zsolt Toth
- University of Florida, Gainesville, Florida, USA
| | | | | | | | - Derek Walsh
- Northwestern University, Chicago, Illinois, USA
| | | | | | | | - Sandra Weller
- University of Connecticut, Farmington, Connecticut, USA
| | - Sean Whelan
- Washington University, St. Louis, Missouri, USA
| | | | | | | | - Scott Wong
- Oregon Health and Science University, Beaverton, Oregon, USA
| | | |
Collapse
|
5
|
Ghasemian K, Broer I, Schön J, Killisch R, Kolp N, Springer A, Huckauf J. Oral and Subcutaneous Immunization with a Plant-Produced Mouse-Specific Zona Pellucida 3 Peptide Presented on Hepatitis B Core Antigen Virus-like Particles. Vaccines (Basel) 2023; 11:vaccines11020462. [PMID: 36851339 PMCID: PMC9963689 DOI: 10.3390/vaccines11020462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 02/14/2023] [Accepted: 02/16/2023] [Indexed: 02/19/2023] Open
Abstract
A short mouse-specific peptide from zona pellucida 3 (mZP3, amino acids 328-342) has been shown to be associated with antibody-mediated contraception. In this study, we investigated the production of mZP3 in the plant, as an orally applicable host, and examined the immunogenicity of this small peptide in the BALB/c mouse model. The mZP3 peptide was inserted into the major immunodominant region of the hepatitis B core antigen and was produced in Nicotiana benthamiana plants via Agrobacterium-mediated transient expression. Soluble HBcAg-mZP3 accumulated at levels up to 2.63 mg/g leaf dry weight (LDW) containing ~172 µg/mg LDW mZP3 peptide. Sucrose gradient analysis and electron microscopy indicated the assembly of the HBcAg-mZP3 virus-like particles (VLPs) in the soluble protein fraction. Subcutaneously administered mZP3 peptide displayed on HBcAg VLPs was immunogenic in BALB/c mice at a relatively low dosage (5.5 µg mZP3 per dose) and led to the generation of mZP3-specific antibodies that bound to the native zona pellucida of wild mice. Oral delivery of dried leaves expressing HBcAg-mZP3 also elicited mZP3-specific serum IgG and mucosal IgA that cross-reacted with the zona pellucida of wild mice. According to these results, it is worthwhile to investigate the efficiency of plants producing HBcAg-mZP3 VLPs as immunogenic edible baits in reducing the fertility of wild mice through inducing antibodies that cross-react to the zona pellucida.
Collapse
Affiliation(s)
- Khadijeh Ghasemian
- Department of Agrobiotechnology and Risk Assessment for Bio and Gene Technology, Faculty of Agricultural and Environmental Sciences, University of Rostock, 18059 Rostock, Germany
| | - Inge Broer
- Department of Agrobiotechnology and Risk Assessment for Bio and Gene Technology, Faculty of Agricultural and Environmental Sciences, University of Rostock, 18059 Rostock, Germany
| | - Jennifer Schön
- Department of Reproduction Biology, Leibniz Institute for Zoo and Wildlife Research (IZW), 10315 Berlin, Germany
| | - Richard Killisch
- BIOSERV, Analytik und Medizinprodukte GmbH, 18059 Rostock, Germany
| | - Nadine Kolp
- BIOSERV, Analytik und Medizinprodukte GmbH, 18059 Rostock, Germany
| | - Armin Springer
- Medical Biology and Electron Microscopy Center, Rostock University Medical Center, 18057 Rostock, Germany
| | - Jana Huckauf
- Department of Agrobiotechnology and Risk Assessment for Bio and Gene Technology, Faculty of Agricultural and Environmental Sciences, University of Rostock, 18059 Rostock, Germany
- Correspondence:
| |
Collapse
|
6
|
Plant-Produced Mouse-Specific Zona Pellucida 3 Peptide Induces Immune Responses in Mice. Vaccines (Basel) 2023; 11:vaccines11010153. [PMID: 36679998 PMCID: PMC9866649 DOI: 10.3390/vaccines11010153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 01/04/2023] [Accepted: 01/06/2023] [Indexed: 01/12/2023] Open
Abstract
Contraceptive vaccines are designed to stimulate autoimmune responses to molecules involved in the reproductive process. A mouse-specific peptide from zona pellucida 3 (mZP3) has been proposed as a target epitope. Here, we employed a plant expression system for the production of glycosylated mZP3 and evaluated the immunogenicity of plant-produced mZP3-based antigens in a female BALB/c mouse model. In the mZP3-1 antigen, mZP3 fused with a T-cell epitope of tetanus toxoid, a histidine tag, and a SEKDEL sequence. A fusion antigen (GFP-mZP3-1) and a polypeptide antigen containing three repeats of mZP3 (mZP3-3) were also examined. Glycosylation of mZP3 should be achieved by targeting proteins to the endoplasmic reticulum. Agrobacterium-mediated transient expression of antigens resulted in successful production of mZP3 in Nicotiana benthamiana. Compared with mZP3-1, GFP-mZP3-1 and mZP3-3 increased the production of the mZP3 peptide by more than 20 and 25 times, respectively. The glycosylation of the proteins was indicated by their size and their binding to a carbohydrate-binding protein. Both plant-produced GFP-mZP3-1 and mZP3-3 antigens were immunogenic in mice; however, mZP3-3 generated significantly higher levels of serum antibodies against mZP3. Induced antibodies recognized native zona pellucida of wild mouse, and specific binding of antibodies to the oocytes was observed in immunohistochemical studies. Therefore, these preliminary results indicated that the plants can be an efficient system for the production of immunogenic mZP3 peptide, which may affect the fertility of wild mice.
Collapse
|
7
|
Yang J, Zhou Z, Li G, Dong Z, Li Q, Fu K, Liu H, Zhong Z, Fu H, Ren Z, Gu W, Peng G. Oral immunocontraceptive vaccines: A novel approach for fertility control in wildlife. Am J Reprod Immunol 2023; 89:e13653. [PMID: 36373212 DOI: 10.1111/aji.13653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 10/29/2022] [Accepted: 11/08/2022] [Indexed: 11/16/2022] Open
Abstract
The overabundant populations of wildlife have caused many negative impacts, such as human-wildlife conflicts and ecological degradation. The existing approaches like injectable immunocontraceptive vaccines and lethal methods have limitations in many aspects, which has prompted the advancement of oral immunocontraceptive vaccine. There is growing interest in oral immunocontraceptive vaccines for reasons including high immunization coverage, easier administration, frequent boosting, the ability to induce systemic and mucosal immune responses, and cost-effectiveness. Delivery systems have been developed to protect oral antigens and enhance the immunogenicity, including live vectors, microparticles and nanoparticles, bacterial ghosts, and mucosal adjuvants. However, currently, no effective oral immunocontraceptive vaccine is available for field trials because of the enormous development challenges, including biological and physicochemical barriers of the gastrointestinal tract, mucosal tolerance, pre-existing immunity, antigen residence time in the small intestine, species specificity and other safety issues. To overcome these challenges, this article summarizes achievements in delivery systems and contraceptive antigens in oral immunocontraceptive vaccines and explores the potential barriers for future vaccine design and application.
Collapse
Affiliation(s)
- Jinpeng Yang
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Ziyao Zhou
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Gangshi Li
- Chengdu Ruipeng Changjiang Road Pet Hospital, Chengdu, Sichuan, China
| | - Zhiyou Dong
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Qianlan Li
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Keyi Fu
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Haifeng Liu
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Zhijun Zhong
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Hualin Fu
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Zhihua Ren
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Wuyang Gu
- Chengdu Ruipeng Changjiang Road Pet Hospital, Chengdu, Sichuan, China
| | - Guangneng Peng
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China
| |
Collapse
|
8
|
Cottingham E, Johnstone T, Hartley CA, Devlin JM. Use of feline herpesvirus as a vaccine vector offers alternative applications for feline health. Vet Microbiol 2021; 261:109210. [PMID: 34416538 DOI: 10.1016/j.vetmic.2021.109210] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 08/15/2021] [Indexed: 12/26/2022]
Abstract
Herpesviruses are attractive vaccine vector candidates due to their large double stranded DNA genome and latency characteristics. Within the scope of veterinary vaccines, herpesvirus-vectored vaccines have been well studied and commercially available vectored vaccines are used to help prevent diseases in different animal species. Felid alphaherpesvirus 1 (FHV-1) has been characterised as a vector candidate to protect against a range of feline pathogens. In this review we highlight the methods used to construct FHV-1 based vaccines and their outcomes, while also proposing alternative uses for FHV-1 as a viral vector.
Collapse
Affiliation(s)
- Ellen Cottingham
- The Asia Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, 3010, Australia.
| | - Thurid Johnstone
- U-Vet Animal Hospital, Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, Victoria, 3030, Australia
| | - Carol A Hartley
- The Asia Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, 3010, Australia
| | - Joanne M Devlin
- The Asia Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, 3010, Australia
| |
Collapse
|
9
|
Shukla S, Hu H, Cai H, Chan SK, Boone CE, Beiss V, Chariou PL, Steinmetz NF. Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy. Annu Rev Virol 2020; 7:559-587. [PMID: 32991265 PMCID: PMC8018517 DOI: 10.1146/annurev-virology-010720-052252] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Viral nanotechnology exploits the prefabricated nanostructures of viruses, which are already abundant in nature. With well-defined molecular architectures, viral nanocarriers offer unprecedented opportunities for precise structural and functional manipulation using genetic engineering and/or bio-orthogonal chemistries. In this manner, they can be loaded with diverse molecular payloads for targeted delivery. Mammalian viruses are already established in the clinic for gene therapy and immunotherapy, and inactivated viruses or virus-like particles have long been used as vaccines. More recently, plant viruses and bacteriophages have been developed as nanocarriers for diagnostic imaging, vaccine and drug delivery, and combined diagnosis/therapy (theranostics). The first wave of these novel virus-based tools has completed clinical development and is poised to make an impact on clinical practice.
Collapse
Affiliation(s)
- Sourabh Shukla
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - He Hu
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Hui Cai
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Soo-Khim Chan
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Christine E Boone
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Veronique Beiss
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Paul L Chariou
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Nicole F Steinmetz
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
- Department of Radiology, University of California, San Diego, La Jolla, California 92093, USA
- Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, USA
- Moores Cancer Center and Center for Nano-ImmunoEngineering, University of California, San Diego, La Jolla, California 92093, USA;
| |
Collapse
|
10
|
Dual-Use and Infectious Disease Research. INFECTIOUS DISEASES IN THE NEW MILLENNIUM 2020. [PMCID: PMC7226902 DOI: 10.1007/978-3-030-39819-4_9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Despite rapid advance in the prevention, diagnosis, and treatment, infectious diseases remain a central challenge for global health policy. In the twenty-first century, the life sciences—including microbiology, virology, and immunology—have been marshalled as key tools in the fight against infectious disease, and the promotion of global health. Rapid advance in these fields, however, has given rise to the “dual-use dilemma,” when one and the same piece of scientific research or technology has the capacity to help or harm humanity. While not unique to fields that address infectious disease, contemporary cases of dual-use research are largely identified in the context of the life sciences. In this chapter I outline the debate about dual-use research in the life sciences, in particular the ethics of dual-use research. After a historical overview of the dual-use dilemma in the twenty-first century, I examine ethical issues in attempting to trade off the risks and benefits of dual-use research. I address how we select alternative, less risky experiments; translational issues arising for dual-use research; and political commitments to realise the benefits and mitigate the risks arising from such research. I then discuss the governance of dual-use research, before concluding with a brief discussion on priority setting in infectious disease research as a path forward for policymakers.
Collapse
|
11
|
Viral Replicative Capacity, Antigen Availability via Hematogenous Spread, and High T FH:T FR Ratios Drive Induction of Potent Neutralizing Antibody Responses. J Virol 2019; 93:JVI.01795-18. [PMID: 30626686 DOI: 10.1128/jvi.01795-18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 12/19/2018] [Indexed: 01/10/2023] Open
Abstract
Live viral vaccines elicit protective, long-lived humoral immunity, but the underlying mechanisms through which this occurs are not fully elucidated. Generation of affinity matured, long-lived protective antibody responses involve close interactions between T follicular helper (TFH) cells, germinal center (GC) B cells, and T follicular regulatory (TFR) cells. We postulated that escalating concentrations of antigens from replicating viruses or live vaccines, spread through the hematogenous route, are essential for the induction and maintenance of long-lived protective antibody responses. Using replicating and poorly replicating or nonreplicating orthopox and influenza A viruses, we show that the magnitude of TFH cell, GC B cell, and neutralizing antibody responses is directly related to virus replicative capacity. Further, we have identified that both lymphoid and circulating TFH:TFR cell ratios during the peak GC response can be used as an early predictor of protective, long-lived antibody response induction. Finally, administration of poorly or nonreplicating viruses to allow hematogenous spread generates significantly stronger TFH:TFR ratios and robust TFH, GC B cell and neutralizing antibody responses.IMPORTANCE Neutralizing antibody response is the best-known correlate of long-term protective immunity for most of the currently licensed clinically effective viral vaccines. However, the host immune and viral factors that are critical for the induction of robust and durable antiviral humoral immune responses are not well understood. Our study provides insight into the dynamics of key cellular mediators of germinal center reaction during live virus infections and the influence of viral replicative capacity on the magnitude of antiviral antibody response and effector function. The significance of our study lies in two key findings. First, the systemic spread of even poorly replicating or nonreplicating viruses to mimic the spread of antigens from replicating viruses due to escalating antigen concentration is fundamental to the induction of durable antibody responses. Second, the TFH:TFR ratio may be used as an early predictor of protective antiviral humoral immune responses long before memory responses are generated.
Collapse
|
12
|
Vectored gene delivery for lifetime animal contraception: Overview and hurdles to implementation. Theriogenology 2018; 112:63-74. [DOI: 10.1016/j.theriogenology.2017.11.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2017] [Revised: 10/25/2017] [Accepted: 11/02/2017] [Indexed: 12/24/2022]
|
13
|
Liu M, Luo R, Wang H, Cao G, Wang Y. Recovery of fertility in quinestrol-treated or diethylstilbestrol-treated mice: Implications for rodent management. Integr Zool 2017; 12:250-259. [PMID: 27611741 DOI: 10.1111/1749-4877.12236] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Fertility control is an alternative strategy to traditional culling for the management of rodent pests. Previous studies have demonstrated that quinestrol is a potential contraceptive for male rodents, but the recovery of fertility in quinestrol-treated rodents has not been evaluated. This study used C57BL/6J mice to evaluate the recovery rate of male fertility after the administration of quinestrol. Diethylstilbestrol (DES), a non-steroid estrogenic compound, was used for comparison. Different groups of mice were treated with 1 mg/kg quinestrol, 1 mg/kg DES, or castor oil separately for 7 days. These mice were then killed on days 8, 22 and 50 respectively. Our results indicated that the weight of epididymides and seminal vesicles decreased significantly on days 8 and 22 in quinestrol/DES-treated mice, with extensive histological changes in the seminiferous tubules. Sperm concentrations in the cauda epididymal fluid were significantly reduced on days 8 and 22 in both quinestrol and DES treatment groups and on day 50 for the DES, but not the quinestrol group. Further analysis revealed that DES-treated mice exhibited a higher proportion of abnormal sperm accumulation in the epididymis, indicating that the normal sperm transportation to the cauda epididymis was blocked. Our results indicate that the anti-fertility effects on male mice given quinestrol were of shorter duration than for those receiving DES at the dose of 1 mg/kg body weight.
Collapse
Affiliation(s)
- Ming Liu
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| | - Rongcan Luo
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| | - Hao Wang
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.,University of the Chinese Academy of Sciences, Beijing, China
| | - Guangming Cao
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.,University of the Chinese Academy of Sciences, Beijing, China
| | - Yanling Wang
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
14
|
Ovarian dysfunction associated with zona pellucida–based immunocontraceptive vaccines. Theriogenology 2017; 89:329-337. [DOI: 10.1016/j.theriogenology.2016.09.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 09/09/2016] [Accepted: 09/09/2016] [Indexed: 11/24/2022]
|
15
|
Affiliation(s)
- R. Mark Buller
- Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, St. Louis, Missouri
| |
Collapse
|
16
|
Buller RM, Connell ND, Morse SS, Campbell M, Tait RC. Strengthening the role of the IBC in the 21st century. ENSURING NATIONAL BIOSECURITY 2016. [PMCID: PMC7149545 DOI: 10.1016/b978-0-12-801885-9.00013-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
The US government (USG) has not fully implemented a robust system to evaluate dual-use research (DUR). In particular, the USG has failed to effectively fund, support, and expand the role of the local Institutional Biosafety Committee in the oversight of DUR and in the changing scientific landscape; a comprehensive education program for all in life sciences research with regard to the dual-use dilemma has not been forthcoming; and finally, there has been no systematic evaluation of the impact of USG policy, regulations, and guidance on an institution’s cost structure and on scientific discovery. We detail our judgments on current USG DUR policy and provide recommendations for future oversight of DUR from our perspective as senior administrators and laboratory scientists charged with the responsibility of conducting life-sciences research in an era of increasing regulatory requirements and decreasing federal support.
Collapse
|
17
|
Evidence for Persistence of Ectromelia Virus in Inbred Mice, Recrudescence Following Immunosuppression and Transmission to Naïve Mice. PLoS Pathog 2015; 11:e1005342. [PMID: 26700306 PMCID: PMC4689526 DOI: 10.1371/journal.ppat.1005342] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 11/24/2015] [Indexed: 12/19/2022] Open
Abstract
Orthopoxviruses (OPV), including variola, vaccinia, monkeypox, cowpox and ectromelia viruses cause acute infections in their hosts. With the exception of variola virus (VARV), the etiological agent of smallpox, other OPV have been reported to persist in a variety of animal species following natural or experimental infection. Despite the implications and significance for the ecology and epidemiology of diseases these viruses cause, those reports have never been thoroughly investigated. We used the mouse pathogen ectromelia virus (ECTV), the agent of mousepox and a close relative of VARV to investigate virus persistence in inbred mice. We provide evidence that ECTV causes a persistent infection in some susceptible strains of mice in which low levels of virus genomes were detected in various tissues late in infection. The bone marrow (BM) and blood appeared to be key sites of persistence. Contemporaneous with virus persistence, antiviral CD8 T cell responses were demonstrable over the entire 25-week study period, with a change in the immunodominance hierarchy evident during the first 3 weeks. Some virus-encoded host response modifiers were found to modulate virus persistence whereas host genes encoded by the NKC and MHC class I reduced the potential for persistence. When susceptible strains of mice that had apparently recovered from infection were subjected to sustained immunosuppression with cyclophosphamide (CTX), animals succumbed to mousepox with high titers of infectious virus in various organs. CTX treated index mice transmitted virus to, and caused disease in, co-housed naïve mice. The most surprising but significant finding was that immunosuppression of disease-resistant C57BL/6 mice several weeks after recovery from primary infection generated high titers of virus in multiple tissues. Resistant mice showed no evidence of a persistent infection. This is the strongest evidence that ECTV can persist in inbred mice, regardless of their resistance status.
Collapse
|
18
|
Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses. J Virol 2014; 89:1889-99. [PMID: 25428875 DOI: 10.1128/jvi.02572-14] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
UNLABELLED Antibody production by B cells in the absence of CD4 T cell help has been shown to be necessary and sufficient for protection against secondary orthopoxvirus (OPV) infections. This conclusion is based on short-term depletion of leukocyte subsets in vaccinated animals, in addition to passive transfer of immune serum to naive hosts that are subsequently protected from lethal orthopoxvirus infection. Here, we show that CD4 T cell help is necessary for neutralizing antibody production and virus control during a secondary ectromelia virus (ECTV) infection. A crucial role for CD4 T cells was revealed when depletion of this subset was extended beyond the acute phase of infection. Sustained depletion of CD4 T cells over several weeks in vaccinated animals during a secondary infection resulted in gradual diminution of B cell responses, including neutralizing antibody, contemporaneous with a corresponding increase in the viral load. Long-term elimination of CD8 T cells alone delayed virus clearance, but prolonged depletion of both CD4 and CD8 T cells resulted in death associated with uncontrolled virus replication. In the absence of CD4 T cells, perforin- and granzyme A- and B-dependent effector functions of CD8 T cells became critical. Our data therefore show that both CD4 T cell help for antibody production and CD8 T cell effector function are critical for protection against secondary OPV infection. These results are consistent with the notion that the effectiveness of the smallpox vaccine is related to its capacity to induce both B and T cell memory. IMPORTANCE Smallpox eradication through vaccination is one of the most successful public health endeavors of modern medicine. The use of various orthopoxvirus (OPV) models to elucidate correlates of vaccine-induced protective immunity showed that antibody is critical for protection against secondary infection, whereas the role of T cells is unclear. Short-term leukocyte subset depletion in vaccinated animals or transfer of immune serum to naive, immunocompetent hosts indicates that antibody alone is necessary and sufficient for protection. We show here that long-term depletion of CD4 T cells over several weeks in vaccinated animals during secondary OPV challenge reveals an important role for CD4 T cell-dependent antibody responses in effective virus control. Prolonged elimination of CD8 T cells alone delayed virus clearance, but depletion of both T cell subsets resulted in death associated with uncontrolled virus replication. Thus, vaccinated individuals who subsequently acquire T cell deficiencies may not be protected against secondary OPV infection.
Collapse
|
19
|
Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier ER, Painter G, Schriewer J, Trost LC, Buller RM. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus. Antiviral Res 2014; 111:42-52. [PMID: 25128688 PMCID: PMC9533899 DOI: 10.1016/j.antiviral.2014.08.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Revised: 07/31/2014] [Accepted: 08/04/2014] [Indexed: 12/02/2022]
Abstract
Natural orthopoxvirus outbreaks such as vaccinia, cowpox, cattlepox and buffalopox continue to cause morbidity in the human population. Monkeypox virus remains a significant agent of morbidity and mortality in Africa. Furthermore, monkeypox virus’s broad host-range and expanding environs make it of particular concern as an emerging human pathogen. Monkeypox virus and variola virus (the etiological agent of smallpox) are both potential agents of bioterrorism. The first line response to orthopoxvirus disease is through vaccination with first-generation and second-generation vaccines, such as Dryvax and ACAM2000. Although these vaccines provide excellent protection, their widespread use is impeded by the high level of adverse events associated with vaccination using live, attenuated virus. It is possible that vaccines could be used in combination with antiviral drugs to reduce the incidence and severity of vaccine-associated adverse events, or as a preventive in individuals with uncertain exposure status or contraindication to vaccination. We have used the intranasal mousepox (ectromelia) model to evaluate the efficacy of vaccination with Dryvax or ACAM2000 in conjunction with treatment using the broad spectrum antiviral, brincidofovir (BCV, CMX001). We found that co-treatment with BCV reduced the severity of vaccination-associated lesion development. Although the immune response to vaccination was quantifiably attenuated, vaccination combined with BCV treatment did not alter the development of full protective immunity, even when administered two days following ectromelia challenge. Studies with a non-replicating vaccine, ACAM3000 (MVA), confirmed that BCV’s mechanism of attenuating the immune response following vaccination with live virus was, as expected, by limiting viral replication and not through inhibition of the immune system. These studies suggest that, in the setting of post-exposure prophylaxis, co-administration of BCV with vaccination should be considered a first response to a smallpox emergency in subjects of uncertain exposure status or as a means of reduction of the incidence and severity of vaccine-associated adverse events.
Collapse
Affiliation(s)
- Scott Parker
- Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, United States
| | - Ryan Crump
- Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, United States
| | - Scott Foster
- Chimerix Inc., 2505 Meridian Parkway, Suite 340, Durham, NC 27713, United States
| | - Hollyce Hartzler
- Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, United States
| | - Ed Hembrador
- Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, United States
| | - E Randall Lanier
- Chimerix Inc., 2505 Meridian Parkway, Suite 340, Durham, NC 27713, United States
| | - George Painter
- Chimerix Inc., 2505 Meridian Parkway, Suite 340, Durham, NC 27713, United States
| | - Jill Schriewer
- Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, United States
| | - Lawrence C Trost
- Chimerix Inc., 2505 Meridian Parkway, Suite 340, Durham, NC 27713, United States
| | - R Mark Buller
- Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, United States.
| |
Collapse
|
20
|
Gupta SK, Shrestha A, Minhas V. Milestones in contraceptive vaccines development and hurdles in their application. Hum Vaccin Immunother 2013; 10:911-25. [PMID: 24262991 DOI: 10.4161/hv.27202] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Contraceptive vaccines have been proposed for controlling the growing human population and wildlife population management. Multiple targets such as gonadotropin releasing hormone (GnRH), luteinizing hormone, follicle stimulating hormone, gonadotropin receptors, sperm-specific proteins and zona pellucida glycoproteins have been exploited to develop contraceptive vaccine and their efficacy investigated and shown in various experimental animal models. Vaccines based on GnRH have found application in immuno-castration of male pigs for prevention of boar-taint. Vaccines based on zona pellucida glycoproteins have shown promising results for population management of wild horses and white-tailed deer. Phase II clinical trials in women with β-human chorionic gonadotropin (β-hCG)-based contraceptive vaccine established proof of principle that these can be developed for human application. Block in fertility by β-hCG contraceptive vaccine was reversible. Further research inputs are required to establish the safety of contraceptive vaccines, improve their immunogenicity and to develop novel vaccine delivery platforms for providing long lasting immunity.
Collapse
Affiliation(s)
- Satish Kumar Gupta
- Reproductive Cell Biology Laboratory; National Institute of Immunology; Aruna Asaf Ali Marg; New Delhi, India
| | | | | |
Collapse
|
21
|
The orchestrated functions of innate leukocytes and T cell subsets contribute to humoral immunity, virus control, and recovery from secondary poxvirus challenge. J Virol 2013; 87:3852-61. [PMID: 23345522 DOI: 10.1128/jvi.03038-12] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A pivotal role for antigen-specific recall responses to secondary virus infection is well established, but the contribution of innate immune cells to this process is unknown. Recovery of mice from a primary orthopoxvirus (ectromelia virus [ECTV]) infection requires the function of natural killer (NK) cells, granulocytes, plasmacytoid dendritic cells (pDC), T cells, and B cells. However, during a secondary challenge, resolution of infection is thought to be dependent on antibody but not T cell function. We investigated the contribution of NK cells, granulocytes, and pDC to virus control during a secondary virus challenge in mice that had been primed with an avirulent, mutant strain of ECTV. Mice depleted of NK cells, granulocytes, or pDC effectively controlled virus, as did mice depleted of both CD4 and CD8 T cell subsets. However, mice concurrently depleted of all three innate cell subsets had elevated virus load, but this was significantly exacerbated in mice also depleted of CD4 and/or CD8 T cells. Increased viral replication in mice lacking innate cells plus CD4 T cells was associated with a significant reduction in neutralizing antibody. Importantly, in addition to T-dependent neutralizing antibody responses, the function of CD8 T cells was also clearly important for virus control. The data indicate that in the absence of innate cell subsets, a critical role for both CD4 and CD8 T cells becomes apparent and, conversely, in the absence of T cell subsets, innate immune cells help contain infection.
Collapse
|
22
|
Kadir Z, Ma X, Li J, Zhang F. Granulocyte-macrophage colony-stimulating factor enhances the humoral immune responses of mouse zona pellucida 3 vaccine strategy based on DNA and protein coadministration in BALB/c mice. Reprod Sci 2012; 20:400-7. [PMID: 23111125 DOI: 10.1177/1933719112459236] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We recently demonstrated that co-administration of mouse zona pellucida 3 (mZP3) DNA and protein vaccine enhanced the contraception of mice by increasing humoral immune responses. In this study, we try to use granulocyte-macrophage colony-stimulating factor (GM-CSF) to further improve the humoral immune responses induced by mZP3 DNA and protein co-administration. BALB/c mice were intranasally pre-injected with GM-CSF 4 days before co-administration. Compared to DNA and protein coadministration without GM-CSF, the combination of GM-CSF and coadministration significantly enhances humoral immune responses, especially the level of secretory immunoglobulin A (sIgA) in vaginal washes. The enhanced antibody responses are correlated with the upregulated level of interleukin 4 (IL-4) and enhanced maturation of dendritic cells (DCs). Thus, GM-CSF is a potential candidate adjuvant to be used for the development of a safe and effective contraceptive vaccine.
Collapse
Affiliation(s)
- Zibirnisa Kadir
- College of Life Science and Technology, Xinjiang University, Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, Urumqi, China
| | | | | | | |
Collapse
|
23
|
Liu M, Wan X, Yin Y, Li YX, Sun F, Zhang Z, Wang YL. Subfertile effects of quinestrol and levonorgestrel in male rats. Reprod Fertil Dev 2012; 24:297-308. [PMID: 22281075 DOI: 10.1071/rd10221] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2010] [Accepted: 05/04/2011] [Indexed: 11/23/2022] Open
Abstract
The contraceptive regimen consisting of levonorgestrel and quinestrol (EP-1) has been shown to be effective in several types of wild rodents. In the present study, we investigated the effect of EP-1 and its two components on fertility and spermatogenesis to elucidate the mechanisms underlying its contraceptive effect. Sprague-Dawley rats were treated with 0.33 mgkg(-1) quinestrol (E group), 0.67 mgkg(-1) levonorgestrel (P group) or their combination (EP group) for 7 days and then killed on Days 21 or 42 after treatment for tissue analysis. On Day 21, the weight of the cauda epididymis decreased significantly, while the weight of the adrenal gland increased significantly in the E and EP groups compared with the weights in the control group. In addition, there was a significant decrease in sperm number in the E and EP groups compared with the control group and there was less staining for the androgen receptor and Wilms' tumour nuclear protein 1 in the E and EP groups. The primary defects in E- or EP-treated rats were abnormal spermiogenesis, lack of elongating spermatids, and pachytene spermatocyte arrest. Analysis of MutL homologue 1 revealed that EP treatment inhibited chromosome recombination during meiosis, but did not cause obvious genetic abnormalities. These data demonstrate that quinestrol, alone or in combination with levonorgestrel, induces subfertility in male rats mainly by interfering with germ cell differentiation. Thus, EP-1 or E alone may be effective contraceptive regimens for fertility control in rodents.
Collapse
Affiliation(s)
- Ming Liu
- State Key Laboratory of Integrated Management of Pest Insets and Rodents, Institute of Zoology, Chinese Academy of Sciences, 1 Beichen West Road, Beijing 100101, China
| | | | | | | | | | | | | |
Collapse
|
24
|
Cross ML, Fleming SB, Cowan PE, Scobie S, Whelan E, Prada D, Mercer AA, Duckworth JA. Vaccinia virus as a vaccine delivery system for marsupial wildlife. Vaccine 2011; 29:4537-43. [DOI: 10.1016/j.vaccine.2011.04.093] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2011] [Revised: 04/19/2011] [Accepted: 04/25/2011] [Indexed: 01/30/2023]
|
25
|
Gupta SK, Srinivasan VA, Suman P, Rajan S, Nagendrakumar SB, Gupta N, Shrestha A, Joshi P, Panda AK. Contraceptive vaccines based on the zona pellucida glycoproteins for dogs and other wildlife population management. Am J Reprod Immunol 2011; 66:51-62. [PMID: 21501280 DOI: 10.1111/j.1600-0897.2011.01004.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Zona pellucida (ZP) glycoproteins, by virtue of their critical role in fertilization, have been proposed as candidate antigens for the development of contraceptive vaccines. In this review, the potential of a ZP-based contraceptive vaccine for the management of wildlife population, with special reference to street dogs, is discussed. Immunization of various animal species, including female dogs, with native porcine ZP led to inhibition of fertility, which was associated with the ovarian dysfunction. Immunization of female dogs with Escherichia coli-expressed recombinant dog ZP glycoprotein-3 (ZP3) either coupled to diphtheria toxoid or expressed as fusion protein with 'promiscuous' T non-B-cell epitope of tetanus toxoid also led to inhibition of fertility. To improve the contraceptive efficacy of ZP-based contraceptive vaccine, various groups are working on improving the immunogen, use of DNA vaccine as prime-boost strategy, and delivering the zona proteins/peptides presented on either virus-like particles or entrapped in microsphere. Host-specific live vectors such as ectromelia virus and cytomegalovirus have also been used to deliver mouse ZP3 in mice. Various studies show the enormous potential of the ZP-based vaccine for the management of wildlife population, where permanent sterilization may be desirable.
Collapse
Affiliation(s)
- Satish K Gupta
- Reproductive Cell Biology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Cross ML, Zheng T, Duckworth JA, Cowan PE. Could recombinant technology facilitate the realisation of a fertility-control vaccine for possums? NEW ZEALAND JOURNAL OF ZOOLOGY 2011. [DOI: 10.1080/03014223.2010.541468] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- ML Cross
- a Landcare Research – Manaaki Whenua , Lincoln, New Zealand
| | - T Zheng
- b AgResearch , Hopkirk Research Institute , Palmerston North, New Zealand
| | - JA Duckworth
- a Landcare Research – Manaaki Whenua , Lincoln, New Zealand
| | - PE Cowan
- c Landcare Research , Palmerston North, New Zealand
| |
Collapse
|
27
|
McLaughlin EA, Aitken RJ. Is there a role for immunocontraception? Mol Cell Endocrinol 2011; 335:78-88. [PMID: 20412833 DOI: 10.1016/j.mce.2010.04.004] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2009] [Revised: 03/31/2010] [Accepted: 04/06/2010] [Indexed: 11/15/2022]
Abstract
The world's population is continuing to grow at an alarming rate and yet no novel methods of contraception have been introduced since 1960s. The paucity of our current contraceptive armoury is indicated by the 46 million abortions that are performed each year, largely in developing countries where population growth is greatest. Thus, whatever new forms of fertility control we develop for the next millennium, the particular needs of developing countries should be borne in mind. Contraceptive vaccines have the potential to provide safe, effective, prolonged, reversible protection against pregnancy in a form that can be easily administered in the Third World. In this review we consider the contraceptive targets that might be pursued, how vaccines might be engineered and the problems generated by inter-individual variations in antibody titre. We conclude that the specifications for a safe, effective, reversible vaccine are more likely to be met in animals than man.
Collapse
Affiliation(s)
- E A McLaughlin
- Discipline of Biological Sciences, School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW 2308, Australia.
| | | |
Collapse
|
28
|
Gupta SK, Gupta N, Suman P, Choudhury S, Prakash K, Gupta T, Sriraman R, Nagendrakumar S, Srinivasan V. Zona pellucida-based contraceptive vaccines for human and animal utility. J Reprod Immunol 2011; 88:240-6. [DOI: 10.1016/j.jri.2011.01.011] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2010] [Revised: 12/26/2010] [Accepted: 01/16/2011] [Indexed: 11/24/2022]
|
29
|
Pallister JA, Halliday DCT, Robinson AJ, Venables D, Voysey RD, Boyle DG, Shanmuganathan T, Hardy CM, Siddon NA, Hyatt AD. Assessment of virally vectored autoimmunity as a biocontrol strategy for cane toads. PLoS One 2011; 6:e14576. [PMID: 21283623 PMCID: PMC3026784 DOI: 10.1371/journal.pone.0014576] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2010] [Accepted: 12/14/2010] [Indexed: 12/04/2022] Open
Abstract
Background The cane toad, Bufo (Chaunus) marinus, is one of the most notorious vertebrate pests introduced into Australia over the last 200 years and, so far, efforts to identify a naturally occurring B. marinus-specific pathogen for use as a biological control agent have been unsuccessful. We explored an alternative approach that entailed genetically modifying a pathogen with broad host specificity so that it no longer caused disease, but carried a gene to disrupt the cane toad life cycle in a species specific manner. Methodology/Principal Findings The adult beta globin gene was selected as the model gene for proof of concept of autoimmunity as a biocontrol method for cane toads. A previous report showed injection of bullfrog tadpoles with adult beta globin resulted in an alteration in the form of beta globin expressed in metamorphs as well as reduced survival. In B. marinus we established for the first time that the switch from tadpole to adult globin exists. The effect of injecting B. marinus tadpoles with purified recombinant adult globin protein was then assessed using behavioural (swim speed in tadpoles and jump length in metamorphs), developmental (time to metamorphosis, weight and length at various developmental stages, protein profile of adult globin) and genetic (adult globin mRNA levels) measures. However, we were unable to detect any differences between treated and control animals. Further, globin delivery using Bohle iridovirus, an Australian ranavirus isolate belonging to the Iridovirus family, did not reduce the survival of metamorphs or alter the form of beta globin expressed in metamorphs. Conclusions/Significance While we were able to show for the first time that the switch from tadpole to adult globin does occur in B. marinus, we were not able to induce autoimmunity and disrupt metamorphosis. The short development time of B. marinus tadpoles may preclude this approach.
Collapse
Affiliation(s)
- Jackie A Pallister
- Australian Animal Health Laboratories, CSIRO Livestock Industries, Geelong, Victoria, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Zhang A, Li J, Zhao G, Geng S, Zhuang S, Wang B, Zhang F. Intranasal co-administration with the mouse zona pellucida 3 expressing construct and its coding protein induces contraception in mice. Vaccine 2011; 29:6785-92. [PMID: 21262188 DOI: 10.1016/j.vaccine.2010.12.061] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The zona pellucida 3 (ZP3), an autoantigen, once used to develop contraceptive vaccine has been faced a safety issue. Avoiding its pathogenic T cell activation, we intranasally co-delivered the mZP3 DNA- and protein-based vaccines in mice and observed that a higher level of sIgA and IgG antibodies in vaginal washes, bronchoalveolar lavages and serum and yielded a lower level of fertility and mean litter size. Importantly, histological analysis showed that normal follicular developments of the infertile mice were not disrupted in the co-delivered group. Thus, the intranasal co-delivery may present a safe strategy for the development of contraceptive vaccine.
Collapse
Affiliation(s)
- Ailian Zhang
- Key Laboratory of Molecular Biology, College of Life Science and Technology, Xinjiang University, Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, Urumqi 830046, PR China
| | | | | | | | | | | | | |
Collapse
|
31
|
Chen N, Bellone CJ, Schriewer J, Owens G, Fredrickson T, Parker S, Buller RML. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy. Virology 2010; 409:328-37. [PMID: 21071055 DOI: 10.1016/j.virol.2010.10.021] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2010] [Revised: 09/14/2010] [Accepted: 10/12/2010] [Indexed: 10/18/2022]
Abstract
In 2001, Jackson et al. reported that murine IL-4 expression by a recombinant ectromelia virus caused enhanced morbidity and lethality in resistant C57BL/6 mice as well as overcame protective immune memory responses. To achieve a more thorough understanding of this phenomenon and to assess a variety of countermeasures, we constructed a series of ECTV recombinants encoding murine IL-4 under the control of promoters of different strengths and temporal regulation. We showed that the ECTV-IL-4 recombinant expressing the highest level of IL-4 was uniformly lethal for C57BL/6 mice even when previously immunized. The lethality of the ECTV-IL-4 recombinants resulted from virus-expressed IL-4 signaling through the IL-4 receptor but was not due to IL-4 toxicity. A number of treatment approaches were evaluated against the most virulent IL-4 encoding virus. The most efficacious therapy was a combination of two antiviral drugs (CMX001(®) and ST-246(®)) that have different mechanisms of action.
Collapse
Affiliation(s)
- Nanhai Chen
- Genelux Corporation, San Diego Science Center, 3030 Bunker Hill Street, Suite 310, San Diego, CA 92109, USA
| | | | | | | | | | | | | |
Collapse
|
32
|
Panchanathan V, Chaudhri G, Karupiah G. Antiviral protection following immunization correlates with humoral but not cell-mediated immunity. Immunol Cell Biol 2010; 88:461-7. [PMID: 20066003 DOI: 10.1038/icb.2009.110] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Smallpox was a deadly disease when it was rife yet despite its eradication more than 30 years ago, the possibility of accidental or intentional release has driven research in search of better definitions of correlates of protective immunity. Mousepox, a disease caused by ectromelia virus (ECTV), is arguably one of the best surrogate small animal models for smallpox. Correlates of protection in mousepox are well defined during primary infection, whereas those in a secondary infection, which have definite relevance to vaccination strategies, are less well understood. We previously established that neutralizing antibody (Ab), which is generated far more rapidly during a secondary infection compared with a primary infection, has a key role during a secondary virus challenge. In this study, we show that the route of immunization or the use of homologous or heterologous virus vaccines for immunization does not influence the ability of mice to control high-dose virulent ECTV challenge or to mount a substantial secondary neutralizing Ab response. In contrast, the recall cytotoxic T lymphocyte (CTL) responses generated under these regimes of immunization were varied and did not correlate with virus control. Furthermore, unlike the recall Ab response that was generated rapidly, the kinetics of the secondary antiviral CTL response was no different to a primary infection and peaked only at day 8 post-challenge. This finding further underscores the importance of Ab in conferring protection during secondary poxvirus infection. This information could potentially prove useful in the design of safer and more efficacious vaccines against poxviruses or other diseases using poxvirus vectors.
Collapse
Affiliation(s)
- Vijay Panchanathan
- Infection and Immunity Group, Program in Immunology, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia
| | | | | |
Collapse
|
33
|
Lapidge SJ, Eason CT, Humphrys ST. A review of chemical, biological and fertility control options for the camel in Australia. RANGELAND JOURNAL 2010. [DOI: 10.1071/rj09033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Since their introduction to Australia in 1840 the one-humped camel, Camelus dromedarius, has gone from the colonist’s companion to a conservationist’s conundrum in the fragile arid ecosystems of Australia. Current management techniques are failing to curb present population growth and alternatives must be sought. This review assess the applicability of currently registered and developmental vertebrate pesticides and fertility control agents for camel control, as well as examining the potential usefulness of known C. dromedarius diseases for biological control. Not surprisingly, little is known about the lethality of most vertebrate pesticides used in Australia to camels. More has been published on adverse reactions to pharmaceuticals used in agriculture and the racing industry. An examination of the literature on C. dromedarius diseases, such as camel pox virus, contagious ecthyma and papillomatosis, indicates that the infections generally result in high morbidity but not necessarily mortality and this alone may not justify their consideration for use in Australia. The possibility exists that other undiscovered or unstudied biological control agents from other camilid species may offer greater potential for population control. As a long-lived species the camel is also not ideally suited to fertility control. Notwithstanding, anti-fertility agents may have their place in preventing the re-establishment of camel populations once they have been reduced through mechanical, biological or chemical means. Delivery of any generic chemical or fertility control agent will, however, require a species-tailored pathway and an appropriate large-scale deployment method. Accordingly, we put forward avenues of investigation to yield improved tools for camel control.
Collapse
|
34
|
Vaccines for immunological control of fertility. Reprod Med Biol 2009; 9:61-71. [PMID: 29699331 DOI: 10.1007/s12522-009-0042-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2009] [Accepted: 11/06/2009] [Indexed: 10/20/2022] Open
Abstract
Vaccines have been proposed as one of the strategies for population control. Immunocontraceptive vaccines can be designed to inhibit: (1) production of gametes (sperm and egg); (2) functions of gametes, leading to blocking of fertilization; and (3) gamete outcome (pregnancy). Immunization with gonadotropin-releasing hormone coupled to different carriers has shown curtailment in the production of sperm with concomitant infertility in various species. Immunization of nonhuman primates and men with ovine follicle stimulating hormone has also resulted in reduced sperm output. Various spermatozoa-specific proteins such as FA1, PH-20, LDH-C4, SP-10, SP-17, sp56, SPAG9, and Izumo have been proposed as candidate antigens to develop contraceptive vaccines, which have shown efficacy in inhibiting fertility in different animal models. Immunization with zona pellucida glycoproteins-based immunogens also results in curtailment of fertility in a variety of species. However, ways to overcome the observed oophoritis associated with zona proteins immunization have yet to be discovered, a necessary step before their proposal for control of human population. Nonetheless, this is a very promising approach to control wildlife animal population. Phase II clinical trials of β-human chorionic gonadotropin-based vaccine in women have established the proof of principle that it is possible to inhibit fertility without any untoward side-effects by vaccination. Further scientific inputs are required to increase the efficacy of contraceptive vaccines and establish their safety beyond doubt, before they can become applicable for control of fertility in humans.
Collapse
|
35
|
Nikolovski S, Lloyd ML, Harvey N, Hardy CM, Shellam GR, Redwood AJ. Overcoming innate host resistance to vaccination: employing a genetically distinct strain of murine cytomegalovirus avoids vector-mediated resistance to virally vectored immunocontraception. Vaccine 2009; 27:5226-32. [PMID: 19591797 DOI: 10.1016/j.vaccine.2009.06.064] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2009] [Revised: 06/17/2009] [Accepted: 06/18/2009] [Indexed: 01/07/2023]
Abstract
The laboratory strain of murine cytomegalovirus (MCMV), K181, has been successfully engineered as a vaccine expressing murine zona pellucida 3 (mZP3) for viral vectored immunocontraception (VVIC) in mice. However, certain laboratory strains of mice are resistant to infection with K181 and therefore demonstrate resistance to VVIC. Cmv1 is the best characterised innate resistance mechanism to MCMV and was first described in C57BL/6 mice. Resistance in C57BL/6 mice is due to early and strong activation of natural killer (NK) cells by an MCMV gene product, m157, that binds directly to the NK cell activating receptor Ly49H. In this study a wild strain of MCMV, G4, which expresses a variant m157 incapable of activating Ly49H, was engineered to express murine zona pellucida 3 (mZP3) and assessed for its ability to sterilise female C57BL/6 mice. When infected with K181-mZP3 female C57BL/6 mice remained fully fertile. In contrast, female C57BL/6 mice were sterilised by a single intraperitoneal inoculation of G4-mZP3. Infertility was induced by G4-mZP3 in three strains of mice that express Ly49H, on two different histocompatibility-2 (H-2) backgrounds. Finally, enhanced immunocontraception was observed in mice expressing H-2(k) mediated resistance to MCMV when infected with G4-mZP3 compared to K181-mZP3. These data indicate that when using viral vaccine vectors, variant vector strains may be used to circumvent powerful innate immune responses against the vector and promote effective vaccination. This study highlights the importance of vaccine vector genetics in vaccination strategies.
Collapse
Affiliation(s)
- Sonia Nikolovski
- Discipline of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, M502, The University of Western Australia, Crawley, WA 6009, Australia
| | | | | | | | | | | |
Collapse
|
36
|
Eade JA, Roberston ID, James CM. Contraceptive potential of porcine and feline zona pellucida A, B and C subunits in domestic cats. Reproduction 2009; 137:913-22. [DOI: 10.1530/rep-08-0471] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Feral cat populations are a major problem in many urban regions throughout the world, threatening biodiversity. Immunocontraception is considered as an alternative and a more humane means to control overpopulation of pest animals than current methods including trapping, poisoning and shooting. In this study, we evaluate porcine zona pellucida (ZP) polypeptide (55 kDa) and feline ZP A, B and C subunits expressed by plasmid vectors as candidate vaccines against fertility in the female domestic cat. Cats were injected subcutaneously with three doses of the ZP vaccines. Vaccinated cats were compared with naïve cats for ZP-antibody response, ovarian histology and fertility after mating. Vaccination with native porcine ZP 55 kDa polypeptide induced anti-porcine ZP antibodies detected by ELISA. However, these antibodies did not cross-react with feline ZP as assessed by immunohistochemistry and no effect on fertilityin vivowas observed after mating. However, vaccination of cats with feline ZPA or feline ZPB+C DNA vectors elicited circulating antibodies specific for feline ZP as assessed by ELISA, with reactivity to native feline ZP in ovarian folliclesin situ. Vaccination with feline ZPA and ZPB+C DNA did not elicit changes in ovarian histology. Although sample sizes were small, conception rates in mated females were 25 and 20% in the ZPA and ZPB+C vaccinated groups respectively, compared with 83% in the control group. We conclude that feline ZPA and ZPB+C subunits are potential candidate antigens for immunocontraceptive vaccines in the domestic cat.
Collapse
|
37
|
Immunogenicity of zona pellucida glycoprotein-3 and spermatozoa YLP12 peptides presented on Johnson grass mosaic virus-like particles. Vaccine 2009; 27:2948-53. [DOI: 10.1016/j.vaccine.2009.03.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2008] [Revised: 03/01/2009] [Accepted: 03/02/2009] [Indexed: 11/15/2022]
|
38
|
O'Leary S, Lloyd ML, Shellam GR, Robertson SA. Immunization with recombinant murine cytomegalovirus expressing murine zona pellucida 3 causes permanent infertility in BALB/c mice due to follicle depletion and ovulation failure. Biol Reprod 2008; 79:849-60. [PMID: 18667753 DOI: 10.1095/biolreprod.108.067884] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
Zona pellucida (ZP) glycoproteins are promising candidate antigens for use in immunocontraceptive vaccines because of their crucial role in mammalian fertilization. A single intraperitoneal immunization with recombinant murine cytomegalovirus engineered to express murine ZP3 (rMCMV-mZP3) induces permanent infertility with no evident systemic illness in female BALB/c mice. To investigate the mechanisms underpinning reproductive failure elicited by rMCMV-mZP3, ovarian parameters and reproductive function were evaluated at time points spanning 10 days to 5 wk after virus inoculation. Fertility was substantially impaired by 14 days after inoculation with rMCMV-mZP3 and was fully ablated by 21 days. Pregnancies established after inoculation but before complete infertility showed no adverse effects on fetal viability assessed at Day 17.5 post coitum (pc). Infertile mice retained estrous cycling activity and remained receptive to mating; however, at Day 3.5 pc there were fewer developing embryos and corpora lutea, plasma progesterone content was reduced, and there was no evidence of excess unfertilized oocytes. Consistent with this, profound ovarian pathology was evident from 10 days after rMCMV-mZP3 inoculation, with a decline first in mature ovarian follicles and then in immature ovarian follicles and with diminished expression of genes regulating follicle development, including Nobox, Gdf9, and Gja1 (connexin43). Follicle loss was associated with mild focal oophoritis and with recruitment of inflammatory leukocytes, predominantly CD4(+) and CD8(+) T cells evident from 10 days after virus inoculation. These data indicate that vaccination with rMCMV-mZP3 causes permanent infertility in BALB/c mice principally due to induction of ovarian autoimmune pathology leading to progressive oocyte depletion and eventual ovulation failure.
Collapse
Affiliation(s)
- Sean O'Leary
- Research Centre for Reproductive Health, Discipline of Obstetrics and Gynaecology, University of Adelaide, Adelaide, South Australia, Australia 5005
| | | | | | | |
Collapse
|
39
|
Li J, Jin H, Zhang A, Li Y, Wang B, Zhang F. Enhanced contraceptive response by co-immunization of DNA and protein vaccines encoding the mouse zona pellucida 3 with minimal oophoritis in mouse ovary. J Gene Med 2008; 9:1095-103. [PMID: 17957814 DOI: 10.1002/jgm.1069] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Zona pellucida 3 (ZP3) acts as the primary sperm receptor, induces autoantibody that can prevent oocyte fertilization and has been proposed as a vaccine candidate for contraception in humans. Due to the elicited autoreactive T cell inflammation that causes ovarian destruction, ZP3-based vaccine with removed T epitopes from the ZP3 is considered as a preferred approach. We present here a new strategy to eliminate the T cell inflammation while retaining a high level of antibody by co-immunization of mZP3 DNA and protein vaccines, which resulted in a higher reduction rate of fertility in this group. Histological analysis showed that there were normal follicular developments of infertile mice in the co-immunized group; while other vaccine groups of the most infertile mice lacked mature follicles. There was a significant correlation between normal follicular development and the inhibition of T cell response in co-immunized mice. At the same time, co-immunization reduced the production of inflammatory cytokine, IFN-gamma, and increased the productions of IL-10 and FoxP3 in CD4 T cells, suggesting the anti-inflammation may be via a T regulatory function. The results indicate that co-immunization of mZP3 DNA- and protein-based vaccines can reduce fertility without interfering with the normal follicular development and present a novel strategy to develop a contraceptive vaccine in humans.
Collapse
Affiliation(s)
- Jinyao Li
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, 830046, P R China
| | | | | | | | | | | |
Collapse
|
40
|
Jacob J, Singleton GR, Hinds LA. Fertility control of rodent pests. WILDLIFE RESEARCH 2008. [DOI: 10.1071/wr07129] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Ricefield rats (Rattus argentiventer) in south-east Asian rice fields and house mice (Mus domesticus) in Australian grain fields are major pest species. They cause damage before and after harvest and carry zoonotic diseases. For both species, management techniques have been pursued using the approach of immunocontraceptive vaccination. We review results from a series of enclosure and field studies conducted with these species to assess the effects of fertility control in small rodents. In the experiments, fertility control was simulated by tubal ligation, ovariectomy or progesterone treatment. A once-off sterilisation of 50–75% of enclosed founder females considerably reduced reproductive output of ricefield rat populations until the end of the reproductive period. In house mice, similar success was achieved when a sterility level of 67% of female founders and offspring was maintained. Repeated antifertility treatments are required because of the much longer breeding period of house mice versus ricefield rats. Comparing the results of enclosure trials with the outcome of simulation models suggests that partial compensation of treatment effects can occur through enhanced reproduction of the remaining fertile females and improved survival of juveniles. However, such compensatory effects as well as behavioural consequences of sterility in field populations are not likely to prevent the management effect at the population level. The challenge for effective fertility control of small rodents in the field is the wide-scale delivery of an antifertility treatment to founders at the beginning of the breeding season and to fertile immigrants that are recruited into the population, which otherwise contribute to the reproductive output at the population level. Future research efforts should focus on species-specific techniques and on agents that can be effectively delivered via bait.
Collapse
|
41
|
Panchanathan V, Chaudhri G, Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol Cell Biol 2007; 86:80-6. [PMID: 17923850 DOI: 10.1038/sj.icb.7100118] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Even though smallpox has been eradicated, the threat of accidental or intentional release has highlighted the fact there is little consensus about correlates of protective immunity or immunity against re-infection with the causative poxvirus, variola virus (VARV). As the existing vaccine for smallpox has unacceptable rates of side effects and complications, new vaccines are urgently needed. Surrogate animal models of VARV infection in humans, including vaccinia virus (VACV) and ectromelia virus (ECTV) infection in mice, monkeypox virus (MPXV) infection in macaques have been used as tools to dissect the immune response to poxviruses. Mousepox, caused by ECTV, a natural mouse pathogen, is arguably the best surrogate small-animal model, as it shares many aspects of virus biology, pathology and clinical features with smallpox in humans. The requirements for recovery from a primary ECTV infection have been well characterized and include type I and II interferons, natural killer cells, CD4T cells, CD8T cell effector function and antibody. From a vaccine standpoint, it is imperative that the requirements for recovery from secondary infection are also identified. We have investigated host immune parameters in response to a secondary ECTV infection, and have identified that interferon and CD8T cell effector functions are not essential; however, T- and B-cell interaction and antibody are absolutely critical for recovery from a secondary challenge. The central role of antibody has been also been identified in the secondary response to other poxviruses. These findings have important clinical implications and would greatly assist the design of therapeutic interventions and new vaccines for smallpox.
Collapse
Affiliation(s)
- Vijay Panchanathan
- Division of Biochemistry and Moelcular Biology, Australian National University, Canberra, Australia.
| | | | | |
Collapse
|
42
|
WILLIAMS CK, DAVEY CC, MOORE RJ, HINDS LA, SILVERS LE, KERR PJ, FRENCH N, HOOD GM, PECH RP, KREBS CJ. Population responses to sterility imposed on female European rabbits. J Appl Ecol 2007. [DOI: 10.1111/j.1365-2664.2006.01264.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Redwood AJ, Smith LM, Lloyd ML, Hinds LA, Hardy CM, Shellam GR. Prospects for virally vectored immunocontraception in the control of wild house mice (Mus domesticus). WILDLIFE RESEARCH 2007. [DOI: 10.1071/wr07041] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The wild house mouse (Mus domesticus) is not native to Australia and was introduced from Europe with early settlement. It undergoes periodic population explosions or plagues, which place significant economic and social burdens on agricultural communities. Present control mechanisms rely on improvements to farm hygiene and the use of rodenticides. This review covers over a decade of work on the use of virally vectored immunocontraception (VVIC) as an adjunct method of controlling mouse populations. Two viral vectors, ectromelia virus (ECTV) and murine cytomegalovirus (MCMV) have been tested as potential VVIC vectors: MCMV has been the most widely studied vector because it is endemic to Australia; ECTV less so because its use would have required the introduction of a new pathogen into the Australian environment. Issues such as efficacy, antigen choice, resistance, transmission, species specificity and safety of VVIC are discussed. In broad terms, both vectors when expressing murine zona pellucida 3 (mZP3) induced long-term infertility in most directly inoculated female mice. Whereas innate and acquired resistance to MCMV may be a barrier to VVIC, the most significant barrier appears to be the attenuation seen in MCMV-based vectors. This attenuation is likely to prevent sufficient transmission for broad-scale use. Should this issue be overcome, VVIC has the potential to contribute to the control of house mouse populations in Australia.
Collapse
|
44
|
McLeod SR, Saunders G, Twigg LE, Arthur AD, Ramsey D, Hinds LA. Prospects for the future: is there a role for virally vectored immunocontraception in vertebrate pest management? WILDLIFE RESEARCH 2007. [DOI: 10.1071/wr07050] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Virally vectored immunocontraception (VVIC) has been studied and promoted as an alternative to lethal methods for vertebrate pest control in Australia and New Zealand. Virally vectored immunocontraception offers a potentially humane and species-specific control method with potential for a good benefit–cost outcome, but its applicability for broad-scale management remains unknown. We present case studies for the house mouse, European rabbit, red fox and common brushtail possum and describe the current status of research into the use of VVIC as a broad-scale pest-management tool. All case studies indicated that there are significant problems with delivery and efficacy. The current state of development suggests that VVIC is not presently a viable alternative for the management of these vertebrate pests, and it is highly unlikely that this will change in the foreseeable future. An absence of benefit–cost data also hinders decision-making, and until benefit–cost data become available it will not be clear if there are short- or long-term benefits resulting from the use of VVIC for broad-scale pest management.
Collapse
|
45
|
Hardy CM, Beaton S, Hinds LA. Immunocontraception in mice using repeated, multi-antigen peptides: immunization with purified recombinant antigens. Mol Reprod Dev 2007; 75:126-35. [PMID: 17474093 DOI: 10.1002/mrd.20745] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Two immunocontraceptive antigens (AgE and AgF) were constructed that included different combinations of highly species-specific peptides from the mouse reproductive antigens SP56, ZP3, ZP2, and ZP1 in the form of multi-antigen peptides (MAPs). Both AgE and AgF contained three tandem repeats each of ZP2 and ZP3 peptide epitopes and a single copy of a ZP1 peptide sequence all of which had previously been demonstrated to individually have immunodominant or contraceptive effects. In addition, AgF contained a single contraceptive peptide derived from SP56, the putative ZP3 receptor protein on sperm. The antigens were expressed and affinity purified as recombinant repeated multi-antigen (polyepitope) peptides using an Escherichia coli maltose binding protein (MBP) expression system. Female BALB/c mice actively immunized with these antigens in Freund's adjuvants produced variable serum antibody responses to the component peptides. Fertility rates for animals immunized with AgE (40%) and AgF (20%) were significantly reduced compared to MBP immunized mice (90%), but the reduction in fertility did not correlate with peptide-specific serum antibody levels. Ovaries from all immunized mice appeared histologically normal with no evidence of oophoritis. These results demonstrate that high levels of immunocontraception can be achieved in mice, without apparent side-effects, using species-specific immunogens that include repeated peptides from proteins involved in fertilization.
Collapse
|
46
|
van Leeuwen BH, Kerr PJ. Prospects for fertility control in the European rabbit (Oryctolagus cuniculus) using myxoma virus-vectored immunocontraception. WILDLIFE RESEARCH 2007. [DOI: 10.1071/wr06167] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Research over the last 15 years has examined whether fertility control can reduce overabundant rabbit populations and whether an effective immunocontraceptive agent can be developed and delivered. The results of this research indicate that for fertility control to have an environmental impact at least 80% of females will need to be infertile and that this infertility will need to be permanent. Epidemiological studies suggest that this level of infertility may be very difficult to obtain with a recombinant myxoma virus because of competition with field strains of virus. Research with laboratory rabbits using recombinant myxoma virus to deliver an immunocontraceptive antigen demonstrated that it was possible to obtain the required level of infertility using rabbit zona pellucida C as an antigen. However, only ~50% of animals remained infertile in the medium term. Further research on delivery vector and antigen selection would be needed to produce a practical immunocontraceptive virus for laboratory testing. Such a virus would then need to be optimised for transmissibility before it would be suitable for field testing.
Collapse
|
47
|
Duckworth JA, Wilson K, Cui X, Molinia FC, Cowan PE. Immunogenicity and contraceptive potential of three infertility-relevant zona pellucida 2 epitopes in the marsupial brushtail possum (Trichosurus vulpecula). Reproduction 2007; 133:177-86. [PMID: 17244744 DOI: 10.1530/rep-06-0088] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In a previous study, three infertility-relevant epitopes of possum ZP2 (Pep12 (amino acids 111–125), Pep31 (amino acids 301–315), and Pep44 (amino acids 431–445)) were identified using sera from possums (Trichosurus vulpecula) immunized with recombinant possum zona pellucida 2 (ZP2) constructs, and a synthetic peptide library of possum ZP2 protein. In this study, the three peptides were conjugated to keyhole limpet hemocyanin and 300 μg of each conjugated peptide were administered subcutaneously to female possums (n = 20 per peptide) in complete Freund’s adjuvant. Immunogen doses were repeated 3 and 6 weeks later using incomplete Freund’s adjuvant. Control animals were immunized with either phosphate-buffered saline only (n = 10) or 300 μg keyhole limpet hemocyanin (n = 10), administered with the same adjuvants. Serum antibodies from animals immunized against these three epitopes bound to the corresponding possum ZP2 peptides, recombinant possum ZP2 protein constructs, and native zona. Possum fertility was assessed following superovulation and artificial insemination. Peptides Pep12 and Pep31 had no significant effects on fertility parameters (P > 0.05). However, animals immunized with Pep44 had lower egg fertilization rates (immunized 19.5% versus control 60.5%, P < 0.05) and produced significantly fewer embryos than control animals (immunized 0.5 embryos versus control 2.4 embryos, P < 0.05). The number of Pep44-immunized females that produced embryos was reduced by 64%. Identification and characterization of possum infertility-relevant epitopes on possum ZP2 protein will assist development of safe, humane, and possum-specific immunocontraceptive vaccines for controlling the introduced possums in New Zealand.
Collapse
Affiliation(s)
- Janine A Duckworth
- National Research Centre for Possum Biocontrol at Landcare Research, PO Box 40, Lincoln 7640, New Zealand
| | | | | | | | | |
Collapse
|
48
|
Strive T, Hardy CM, Reubel GH. Prospects for immunocontraception in the European red fox (Vulpes vulpes). WILDLIFE RESEARCH 2007. [DOI: 10.1071/wr07007] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The European red fox is an introduced pest species in Australia for which improved means of control are urgently needed. Research efforts have focussed recently on the development of novel biological control methods to reduce the serious impact this species continues to have on both native fauna and the sheep industry. The ultimate goal has been to generate an antifertility vaccine for use on foxes that relies on a process termed ‘immunocontraception’. A variety of proteins derived from sperm and oocytes, together with different delivery vectors, have been experimentally assessed for their ability to induce immunocontraceptive responses in foxes. Vaccine vectors screened have included Salmonella typhimurium, vaccinia virus and canine herpesvirus but suppression of fertility has yet to be achieved with any combination of antigen and delivery vector. Downregulation of fox mucosal antibodies during oestrus, lack of vector replication and low antibody responses to the target antigens have been the main constraints in successful fertility control. The fox is not well known as an experimental animal and the logistics of dealing with this difficult-to-handle species proved to be a major challenge when compared with other species, such as rabbits and mice. Despite these difficulties, research on fox immunocontraception has generated important insights into the reproductive biology, husbandry, biology and basic immunology of viral vectors in European red foxes. This information represents a valuable knowledge base should antifertility vaccination for foxes be revisited in the future.
Collapse
|
49
|
Hardy CM, Hinds LA, Kerr PJ, Lloyd ML, Redwood AJ, Shellam GR, Strive T. Biological control of vertebrate pests using virally vectored immunocontraception. J Reprod Immunol 2006; 71:102-11. [PMID: 16870262 DOI: 10.1016/j.jri.2006.04.006] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2006] [Accepted: 04/20/2006] [Indexed: 10/24/2022]
Abstract
Species-specific viruses are being genetically engineered to produce contraceptive biological controls for pest animals such as mice, rabbits and foxes. The virus vaccines are intended to trigger an autoimmune response in the target animals that interferes with their fertility in a process termed virally vectored immunocontraception. Laboratory experiments have shown that high levels of infertility can be induced in mice infected with recombinant murine cytomegalovirus and ectromelia virus expressing reproductive antigens as well as in rabbits using myxoma virus vectors. The strategies used to produce and deliver species-specific immunocontraceptive vaccines to free-living wildlife are presented in this review. Discussion includes coverage of the likely safety of the proposed vaccines as well as the implications of the approach for fertility control in other species.
Collapse
Affiliation(s)
- C M Hardy
- Division of Entomology, Commonwealth Industrial and Scientific Research Organisation, GPO Box 1700, Canberra, ACT, Australia.
| | | | | | | | | | | | | |
Collapse
|
50
|
Redwood AJ, Harvey NL, Lloyd M, Lawson MA, Hardy CM, Shellam GR. Viral vectored immunocontraception: screening of multiple fertility antigens using murine cytomegalovirus as a vaccine vector. Vaccine 2006; 25:698-708. [PMID: 17070624 DOI: 10.1016/j.vaccine.2006.08.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2005] [Revised: 08/08/2006] [Accepted: 08/13/2006] [Indexed: 12/01/2022]
Abstract
Mouse cytomegalovirus (MCMV) has previously been used as a vaccine vector for viral vectored immunocontraception (VVIC). MCMV expressing murine zona pellucida 3 (mZP3) induces long term infertility in up to 100% of female BALB/c mice following a single inoculation. Whilst a large number of antigens have been investigated as potential immunocontraceptive vaccines, it has been difficult to compare these antigens as few studies have used identical approaches or even animal species. Here a range of protein and polyepitope antigens, all expressed by MCMV, were tested for the ability to sterilise female mice. The antigens tested were bone morphogenic protein 15 (BMP15), oviduct glycoprotein (OGP) and ubiquitin-tagged mZP3. In addition, four polyepitope constructs that contain rodent or mouse specific epitopes were tested. This study found that when expressed by an MCMV vector, only full-length mZP3 or ubiquitin-tagged mZP3 induced infertility in female mice. BMP15 and OGP had no effect. Of the four polyepitopes tested, one had a partial effect on fertility. These data indicate that while MCMV is an effective vector for VVIC, the antigen used needs to be tested empirically. The partial infertility seen in mice infected with one of the polyepitope vaccines is a promising finding suggesting that it may be possible to combine a species specific virus with a species specific antigen for use as a disseminating mouse control agent.
Collapse
Affiliation(s)
- Alec J Redwood
- Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, M502, The University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia.
| | | | | | | | | | | |
Collapse
|